Successful ECT treatment for medically refractory nonconvulsive status epilepticus in pediatric patient

Hae W Shin1, Cormac A O'Donovan, Jane G Boggs

  • 1Department of Neurology, Wake Forest University North Carolina Baptist Hospital, Winston-Salem, NC, USA. hshin7507@gmail.com

Seizure
|February 22, 2011
PubMed

Insights

Electroconvulsive therapy (ECT) offers a successful treatment for medically refractory nonconvulsive status epilepticus (NCSE) in pediatric patients. This approach was effective even without fully discontinuing antiepileptic drugs (AEDs).

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Epileptology

Background:

  • Status epilepticus (SE) is a critical neurological emergency with high mortality, especially in refractory cases.
  • Limited consensus exists for third and fourth-line treatments in refractory SE.
  • Electroconvulsive therapy (ECT) is an established treatment for refractory epilepsy and SE, but its pediatric use is infrequent.

Observation:

  • A 7-year-old pediatric patient presented with medically refractory nonconvulsive status epilepticus (NCSE).
  • Conventional antiepileptic drug (AED) therapies were insufficient.
  • ECT was considered as a subsequent treatment option.

Findings:

  • Electroconvulsive therapy (ECT) was successfully administered to treat the pediatric patient's refractory NCSE.
  • The treatment was effective without requiring complete withdrawal of existing antiepileptic drugs (AEDs).
  • This case demonstrates the successful application of ECT in a challenging pediatric neurological condition.

Implications:

  • ECT can be a viable and effective therapeutic option for pediatric nonconvulsive status epilepticus (NCSE) that is resistant to standard treatments.
  • This case expands the understanding of ECT's utility in pediatric neurology.
  • Further research into ECT protocols for pediatric refractory SE and NCSE is warranted.

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: